SCIENTIFIC REPORTS

OPEN

Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity

Yingying Huang*, Qiqi Mao*, Jian He*, Jing Su, Yi Peng, Wei Liang, Zixi Hu, Sufang Zhou, Xiaoling Lu & Yongxiang Zhao

Received: 08 December 2016

Accepted: 17 March 2017

Published: 24 April 2017

To explore dendritic cells/tumor-derived endothelial cells (DC/EC) fusion cells are potent stimulators of T cells to impact tumor progression. ECs were isolated from mice hepatoma cell line (H22) Xenograft, and dendritic cells were isolated from bone marrow of BALB/c mice, then the isolated ECs were cultured and detected the endothelial surface expression of CD105 by flow cytometry. The endothelial characteristics of ECs were detected by tube formation assay and Dil-Ac-LDL uptake assay. After the fusion with polyethylene glycol (PEG), we used DCs, ECs, DCs mixed ECs as the control groups, DC/EC fusion cells as the experimental group, Secretion of IFN- α and IFN- γ was evaluated, T lymphocyte proliferation and cytotoxic T lymphocytes (CTL) were detected *in vitro*. *In vivo*, T lymphocyte induced by five groups was injected to detect the effect of tumor progression. Purified ECs (CD105⁺) took the function of endothelial cells, then successfully fused with DCs. The DC/EC fusion cells were functional in stimulating the proliferation of T cells, which produced IFN- α and IFN- γ . *In vivo*, T cells stimulated by DC/EC fusion cells effectively repressed tumor growth. The fusion cells, which was capable of stimulating T cells, is indispensable for antitumor immunity.

Dendritic Cells (DCs) are regarded as antigen-presenting cells, which has the capacity of eliciting primary immune responses^{1,2}. DCs collect and dispose the antigens into peptides, then DCs present peptides in MHC classes I and II and costimulatory molecules for identification by T cells^{1,3,4}.

Angiogenesis plays a significant role in promoting tumor progression. Tumor development beyond 1–2 mm is dependent on the formation of a functional blood supply system for nutrient delivery. Based on previous studies involving established cell lines or vessels, the blood vessels of tumor and those of normal tissues differ in permeability, composition of the basement membrane, extracellular matrix and cellular composition^{5–7}. When compared to normal blood vessels, tumor vessels are tortuous, poor organizational characteristics, high permeability and inclined to leaky take the macromolecules of tumor microenvironment to blood circulation^{8,9}. Normal vascular endothelial cells derived from embryos, while about 50% to 60% of tumor vascular endothelial cells derived from tumor stem cells, coexpress the specific antigens of tumor cells^{10,11}. Tumor vascular endothelial cells can split proliferation continuously, however normal vascular endothelial cells could not¹². CD105 has been suggested to be the most suitable marker available to quantify tumor angiogenesis, which was observed in tissues undergoing active angiogenesis, whereas absent in blood vessels within normal tissues¹³. In this study, the tumor vascular endothelial cells we selected all express CD105. Thus, it plays an essential role of anti-cancer therapy by targeting tumor endothelial cells.

Previously strategy is the fusion of DCs and tumor cells^{14–16}. In this approach, tumor-derived endothelial Ags are delivered to DCs. Such as APCs, the fusion cells (DC/EC) function with the ability to migrate to draining lymph nodes, where they interact with T cells and induce effective antitumor immunity^{17–19}. These results make clear that tumor-derived endothelial Ag presentation targeting activation of T cells is necessary in antitumor immunity.

National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Shuang Yong Rd. 22, Nanning 530021, P. R. China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to X.L. (email: luwuliu@163.com) or Y. Z. (email: yongxiang_zhao@126.com)

Figure 1. Purification and characterization of CD105⁺ cells. (a) Flow cytometry plot data obtained using CD105⁺ antibody to quantify endothelial cells. (b) CD105⁺ cells take up acetylated LDL compared to CD105⁻ cells and H22 cell lines. (c) CD105⁺ cells form capillary-like networks on Matrigel compared to CD105⁻ cells and H22 cell lines. Scale bars = 100 μm in (b), =200 μm in c. *** $P < 0.001$.

Results

Purification and characterization of CD105⁺ cells. CD105⁺ cells were purified from H22 Xenografts by magnetic activated cell sorting (MACS)²⁰, CD105⁺ and CD105⁻ cells were separated from the single cell suspensions and analyzed the expression of CD105 by flow cytometry. The fractions of CD105 expression cells in CD105⁺ cells or CD105⁻ cells of tumor Xenograft were $97.6 \pm 1.4\%$ and $0.3 \pm 0.1\%$. These results indicate an excellent enrichment of CD105⁺ subpopulations by the magnetic cell separation (Fig. 1a). To compare the endothelial cell function of CD105⁺ cells with that of CD105⁻ cells, tube formation assay and Dil-Ac-LDL uptake assay were detected. In Fig. 1b and c, CD105⁺ cells from tumor tissue showed Dil-Ac-LDL up-take and formation of endothelial tubes, respectively. These results suggested that CD105⁺ cells took of endothelial cell function.

Characterization of the DC/EC fusion cells. Immunofluorescence was used to assess efficiency of the fusions. In Fig. 2a, endothelial cells dyed CFSE, DCs dyed PKH26 and the fusion cells (DC/EC) expressed both of fluorescence. These findings demonstrate the formation of heterokaryons by fusing endothelial cells to DC successfully.

Figure 2. Phenotype of DC/EC and stimulation of antitumor CTL cells by DC/EC. (a) ECs were stained with CFSE (Green), DCs were stained with PKH26 (Red) and the nuclear were stained with DAPI (Blue). Scale bars = 100 μ m. (b) Cultured with DC only, EC only, DC mixed with EC, or DC/EC fusion, then the stimulated T cells were incubated with PKH-26-labeled target ECs at the indicated effector-to-target cell (10:1, 20:1, 30:1), and then detected for lysis. (c) The proliferation of T cells was measured after cultured with DC only, EC only, DC mixed with EC, or DC/EC fusion. (d) The IFN- α and IFN- γ production of T cells were analyzed by ELISA. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Induction of endothelial/Fusion Cells (FCs)-specific CTL responses by four types of cell preparations. To investigate the Ag-specific CTL induction capacity by four types of cell preparations, cytotoxicity assays were performed. Incubation of the endothelial/FCs-stimulated T cells demonstrated selective lysis of the tumor endothelium, while there was no significant lysis of the DC only, EC only, DC mixed with EC (Fig. 2b). These results indicate that T cells stimulated by DC/EC fusion cells had selective lysis of tumor endothelium.

Stimulation of T cell proliferation compromised in fusion cells. To determine the ability of fusion cells about stimulating T cell proliferation, flow cytometry (Beckman Coulter Epics XL, USA) was applied. T cells co-cultured with DC/EC fusion cells proliferated vigorously, co-cultured of these T cells with DC only, EC only, DC mixed with EC resulted in proliferation of T cells, however, at a lower level (Fig. 2c).

Figure 3. T cells activated by DC/EC fusion inhibit H22 Xenograft growth *in vivo*. (a) Photograph of tumor tissues dissected from mice. (b) Tumor volume measured every 5 days by caliper measurement up to 20 days. (c) Average Xenograft tumor weights at 20 days. $n = 3$. $**P < 0.01$, $***P < 0.001$.

IFN- α and IFN- γ production of T cells by four types of cell preparations. To compare the activation of T cells by four types of cell preparations, we detected IFN- α and IFN- γ production by ELISA. The group of DC/EC fusion cells were superior in producing IFN- α and IFN- γ in T cells. In contrast, however, there was little, if any, IFN- α and IFN- γ production in T cells co-cultured with cell suspensions of DC only, EC only, DC mixed with EC (Fig. 2d).

DC/EC fusion cells induce antitumor activity. To assess the induction of antitumor immunity, mice were immunized with irradiated DC, EC, DC mixed with EC or DC/EC fusion cells and then challenged intravenously with 2×10^5 viable H22 cells. In Fig. 3a, immunization of DC/EC fusion cells significantly decreased the tumorigenicity of H22 in BALB/c mice. The tumor volume and weight of the DC/EC fusion cells group was significantly decreased compared to the PBS group (Fig. 3b and c). These findings indicate that T cells induced by DC/EC fusion cells is effective in anti-tumor activity.

Cell proliferation, endothelial cell expression and cell apoptosis in H22 Xenograft. In Fig. 4a, the result showed that there was a significantly increase in apoptosis in DC/EC fusion groups when compared to other groups. We explored the function of activated T cells by immunization, which was confirmed by IHC staining using Ki-67 and CD105 antibody (Fig. 4b and c). T cells induced by DC/EC fusion cells led to low level of Ki-67 protein and CD105 protein expression compared to that by mixed with DC and EC, DC only, EC only or PBS. Importantly, we found no toxicity in heart, lung, liver or kidney tissues of mice injected with T cells induced by immunization (Fig. 4d). These data indicate that T cells induced by DC/EC fusion cells can enhance antitumor immunity.

Discussion

During the development of immune system, body can produce immune tolerance to autologous antigen, so in a healthy state, the body's immune system will not produce an immune response to normal tissue. Previous study found that in situations where a tumor-associated antigen exists but remains unidentified, an approach may be needed for presentation of that antigen by a professional antigen-presenting cell (APC)²¹. Stimulus for DCs activation is in combination with Ags, mature DCs induce an effective anti-tumor immunity^{22–27}. The DC/tumor fusion is an effective approach, because multiple tumor-associated Ags, including those known and unknown, are endogenously processed and presented by MHC class I and II pathways with the ability to migrate to draining lymph nodes^{28–35}. In previous studies, DC-Tumor fusion have been found to have the effective treatment in carcinomas, lymphomas, and melanomas in mice^{14,36–41}. These findings have recently been extended to the treatment

Figure 4. T cells activated by DC/EC fusion impact tumor apoptosis, proliferation and endothelial cell expression *in vivo*. (a) TUNEL expression in tumor tissues and quantitation of its expression. (b) Ki-67 expression in tumor tissues and quantitation of Ki-67 expression. (c) CD105 expression in tumor tissues. (d) HE staining of mice organs to determine toxicity of tissues. Scale bars = 100 μ m in a, = 50 μ m in b and d, = 200 μ m in (c). ** P < 0.01, *** P < 0.001.

and long-term survival of patients^{14,42–45}. However, the fusion of DCs with tumor-derived endothelial cells and its function is largely unknown.

In this experimental setting, T cells are stimulated by four kinds of cell suspensions (DC only, EC only, DC mixed with EC, DC/EC fusion). The results demonstrate that T cells activated by DC/EC fusion cells are effective in protecting mice against tumor challenge. In this context, fusion of tumor-derived endothelial cells with DCs may result in heterokaryons that express the necessary MHC, DC/EC fusions as compared with mixed DC with EC, DC only or EC only, were sufficient to give rise to T cell proliferation, IFN- α , IFN- γ production and CTL responses. T cells treat neovascular antigens of tumor vascular endothelial cells as heterologous antigens (such as CD105). When these antigens are largely and stably presented to T cells by DCs, could activate the specific T cells, kill tumor vascular endothelial cells, but not target normal blood vessels²¹.

In conclusion, we have isolated and generated tumor-derived endothelial cells and DCs from tumor-bearing mice with success. Immunogenic cells created by DC/EC fusions have the capacity to greatly stimulate EC-specific T cells. Our findings that T cells activated by DCs fused with tumor-derived endothelial cells could induce higher levels of IFN- α and IFN- γ , as well as significantly reinforce CTL responses *in vitro* or *in vivo*, which may help in designing optimal strategies for the therapy and may improve DC/EC fusion-based vaccination strategies.

Materials and Methods

DC generation. DCs were obtained from bone marrow of BALB/c mice¹⁷. BALB/c mice were obtained from Vital River Company (Beijing, China) and were housed and cared for in accordance with the Federation of European Laboratory Animal Science Association guidelines, and all protocols were approved by the Animal Ethics Committee of Guangxi Medical University (Nanning, Guangxi, China). Briefly, bone marrow cells were flushed and cultured in RPMI 1640 medium supplemented with 20 ng/ml murine rGM-CSF (Sigma-Aldrich). After five days of culture, DCs were purified and harvested for fusion to endothelial cells.

Preparation of endothelial cells. Tumors were removed from BALB/c mice bearing H22 and placed in cold PBS solution with 50 units/ml heparin. Peripheral and necrotic tissues were excised and remaining tumor was minced by using a scalpel. Dissociation of $0.1 \times 0.1 \times 0.1$ cm³ minced tissue was performed in a 37 °C enzyme cocktail of 10 mg collagenase type I, 20 ml DMEM, 2 ml FBS for 60 min of constant mixing with vortex. The cell suspension was passed through 80 mesh strainer, PBS solution washed, then the cells were resuspended in 100 μ l 0.01 M PBS buffer. Single cells were magnetically labeled with anti-CD105 Microbeads (Miltenyi Biotec) in the dark at 4 °C for 30 min and applied to the prepared MS Column (Miltenyi Biotec). CD105⁺ cells bound to the beads were flushed out by applying the plunger supplied with the column. Then, the sorted CD105⁺ cells were cultured by Endothelial Cell Medium (ScienCell).

Flow Cytometry. For flow cytometry, cells were stained at the concentration of 1×10^6 cells per 95 μ l buffer and 5 μ l phycoerythrin-conjugated anti-CD105 (ebioscience) at 4 °C for 30 min before flow cytometry analysis. All data were analyzed by EXPO32 Software.

Tube Formation Assay. To analyze the tube formation ability of CD105⁺ cells, 100 μ l/well of growth factor-reduced Matrigel (BD Bioscience) was laid into 96-well plates to solidify. Cells were seeded into 96-well plates. After 6 h, the tube formation was assessed with microscopy²⁰.

Dil-Ac-LDL Uptake Assay. CD105⁺ cells were plated into the 6-well plates at 5×10^4 cells/dish. At 75% confluence, the culture medium was replaced by the serum-free DMEM for 24 h, followed by incubation with 2 μ g/ml Dil-Ac-LDL for 5 h in incubator. Then cells were washed and fixed with paraformaldehyde (4 °C, 30 min), followed by DAPI staining for 3 min. The Dil-Ac-LDL uptake was assessed with microscopy²⁰.

Fusion of DCs with endothelial cells (DC/EC). DCs were incubated with ECs for 5 min at a ratio of 10:1 in serum-free medium, which contained 50% polyethylene glycol. Then, culture medium was added to dilute the polyethylene glycol slowly. After washing, the cells were cultured in RPMI 1640 medium (10% FBS, 500 U/ml GM-CSF) for 7–14 days.

Cell proliferation assay. The effects of T cells co-cultured with DC only, EC only, DC mixed with EC, or DC/EC fusion cells on cells proliferation was examined at stimulate cells : T cells (S : T cells) ratios by flow cytometry (Beckman Coulter Epics XL, USA).

Cytotoxicity assays. T cells were stimulated and harvested, which were treated as effector cells in CTL assays^{46,47}. The effects of T cells co-cultured with DC only, EC only, DC mixed with EC and DC/EC fusion cells for 5 hours, respectively. After T cells stimulation, 2×10^4 PKH-26 (Sigma-Aldrich) labeled-target ECs were cultured with T cells (37 °C, 5 h). Cytotoxicity assays were examined at the indicated effector-to-target cell (E:T) ratios by flow cytometry (Beckman Coulter Epics XL, USA).

ELISA. In order to assess the production of IFN- α or IFN- γ in T cells, DC only, EC only, DC mixed with EC, or DC/EC fusion cells were washed twice and cocultured with T cells (1×10^5 cells) at a ratio of 1:10 in 48-well plates at 37 °C for 3 days in the absence of IL-2. T cells were purified and cultured in the low-dose of IL-2 (10 U/ml) for 3 days. The test supernatants from these samples were collected and tested for IFN- α and IFN- γ production by ELISA (BD Pharmingen) according to manufacturer's instructions.

Proliferation assay (*In vivo*). BALB/c mice (Four weeks old, female) were purchased from Guangxi Laboratory Animal Center (Nanning, China). All animal care and experimental procedures were according to guidelines of the Institutional Animal Care and Use Committee of Guangxi Medical University. Left flanks of ten mice were implanted subcutaneously with 1×10^5 H22 (mice hepatoma cell lines) suspended in 0.01 M PBS. Tumor volumes were calculated by the formula. $0.52 \times a \text{ (length)} \times b \text{ (width)}^2$ in millimeters. The animals were sacrificed and the tumors were excised after 40 days.

Immunohistochemistry. In order to quench endogenous peroxidase activities, 4 μm -thick tumor sections were made and incubated with 3% hydrogen peroxide. Heat mediation in citrate buffer (pH 6.0) was used to retrieve antigen. After blocking with 10% goat serum, the slides was incubated with primary antibody. Then, the samples were incubated with the antibodies against Ki-67^{48,49} (Abcam) or CD105⁹ (Abcam) overnight in a humidified container at 4 °C. 0.01 M PBS without primary antibodies was applied as the negative control. Immunohistochemical staining was performed with DAB and were counterstained with hematoxylin. Instead of adding antibody, TUNEL reaction mixture (R&D Systems, Minneapolis, MN) was then added to tumor sections, followed by incubation in a humidified chamber at 37 °C for 60 min and DAPI staining for 3 min.

Statistical analysis. Quantitative data were expressed as mean $\pm$ SD. One-way analysis of variance was used to determine significance. The difference was significant when *P* values were < 0.05 .

References

1. Ardouin, L. *et al.* Broad and Largely Concordant Molecular Changes Characterize Tolerogenic and Immunogenic Dendritic Cell Maturation in Thymus and Periphery. *Immunity* **45**, 305–318 (2016).
2. Anguille, S. *et al.* Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. *Pharmacological Reviews* **67**, 731–753 (2015).
3. Carmi, Y. *et al.* Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. *Nature* **521**, 99–104 (2015).
4. Alatrash, G., Daver, N. & Mittendorf, E. A. Targeting Immune Checkpoints in Hematologic Malignancies. *Pharmacol Rev* **68**, 1014–1025 (2016).
5. Anders, K. *et al.* Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. *Cancer Cell* **20**, 755–767 (2011).
6. Barclay, A. N. & Van den Berg, T. K. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. *Annu Rev Immunol* **32**, 25–50 (2014).
7. Bengsch, B. *et al.* Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. *Immunity* **45**, 358–373 (2016).
8. Latham, S. L. *et al.* Immuno-analysis of microparticles: probing at the limits of detection. *Scientific Reports* **5**, 16314 (2015).
9. Kitajima, Y. *et al.* Estrogen deficiency heterogeneously affects tissue specific stem cells in mice. *Scientific Reports* **5**, 12861 (2015).
10. Ricci-Vitiani, L. *et al.* Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature* **468**, 824–828 (2010).
11. Cheng, L. *et al.* Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. *Cell* **153**, 139–152 (2013).
12. Wang, R. *et al.* Glioblastoma stem-like cells give rise to tumour endothelium. *Nature* **468**, 829–833 (2010).
13. Bellone, Abnormal expression of Endoglin and its receptor complex (TGF- β 1 and TGF- β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa. *International Journal of Oncology* **37** (2010).
14. Choi, B. *et al.* Effective Delivery of Antigen-Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection. *ACS Nano* **10**, 7339–7350 (2016).
15. Chen, F. *et al.* Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. *Scientific Reports* **4**, 5080 (2014).
16. Bhattacharya, N. *et al.* Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer. *Immunity* **45**, 641–655 (2016).
17. Kranz, L. M. *et al.* Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature* **534**, 396–401 (2016).
18. Han, J. *et al.* CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. *Scientific Reports* **5**, 11483 (2015).
19. Blackburn, J. S. *et al.* Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. *Cancer Cell* **25**, 366–378 (2014).
20. Mao, Q. *et al.* A novel method for endothelial cell isolation. *Oncology Reports* (2015).
21. Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. *Nat Med* **3**, 558–561 (1997).
22. Tong, L. *et al.* Fibroblast Growth Factor-10 (FGF-10) Mobilizes Lung-resident Mesenchymal Stem Cells and Protects Against Acute Lung Injury. *Scientific Reports* **6**, 21642 (2016).
23. Slevin, M. *et al.* Monomeric C-reactive protein—a key molecule driving development of Alzheimer's disease associated with brain ischaemia? *Scientific Reports* **5**, 13281 (2015).
24. Pulendran, B. The varieties of immunological experience: of pathogens, stress, and dendritic cells. *Annual Review of Immunology* **33**, 563–606 (2015).
25. Brechmann, M. *et al.* A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes. *Immunity* **37**, 697–708 (2012).
26. Muranski, P. *et al.* Th17 cells are long lived and retain a stem cell-like molecular signature. *Immunity* **35**, 972–985 (2011).
27. Narayan, N. *et al.* The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. *Nature* **492**, 199–204 (2012).
28. Garcia, J. *et al.* Characterisation of synovial fluid and infrapatellar fat pad derived mesenchymal stromal cells: The influence of tissue source and inflammatory stimulus. *Scientific Reports* **6**, 24295 (2016).
29. Zou, L. *et al.* A simple method for deriving functional MSCs and applied for osteogenesis in 3D scaffolds. *Scientific Reports* **3**, 2243 (2013).
30. Vereb, Z. *et al.* Role of Human Corneal Stroma-Derived Mesenchymal-Like Stem Cells in Corneal Immunity and Wound Healing. *Scientific Reports* **6**, 26227 (2016).
31. Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. *Immunity* **39**, 49–60 (2013).
32. Hinrichs, C. S. & Restifo, N. P. Reassessing target antigens for adoptive T-cell therapy. *Nat Biotechnol* **31**, 999–1008 (2013).
33. Maliar, A. *et al.* Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. *Gastroenterology* **143**, 1375–1384 e1371–1375 (2012).

34. Palazon, A. *et al.* The HIF-1 α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. *Cancer Discov* **2**, 608–623 (2012).
35. Methner, A. & Zipp, F. Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS. *Nat Rev Neurol* **9**, 72–73 (2013).
36. Das, P. *et al.* Phosphorylation of Nonmuscle myosin II-A regulatory light chain resists Sendai virus fusion with host cells. *Scientific Reports* **5**, 10395 (2015).
37. Dudda, J. C. *et al.* MicroRNA-155 is required for effector CD8 + T cell responses to virus infection and cancer. *Immunity* **38**, 742–753 (2013).
38. Delgoffe, G. M. *et al.* Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. *Nature* **501**, 252–256 (2013).
39. Linnemann, C. *et al.* High-throughput identification of antigen-specific TCRs by TCR gene capture. *Nat Med* **19**, 1534–1541 (2013).
40. Escobar, G. *et al.* Genetic engineering of hematopoiesis for targeted IFN- α delivery inhibits breast cancer progression. *Sci Transl Med* **6**, 217ra213 (2014).
41. Hossain, D. M. *et al.* FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. *Immunity* **39**, 1057–1069 (2013).
42. Abhishek, D., Garg, L. V., Carolien, Koks, Tina, Verschuere, Louis, Boon, Stefaan, W. & Van Gool, P. A. Dendritic cell vaccines based on imm Source Sci Transl Med SO 2016 Mar 2 8 328 328ra27[PMIDT26936504].pdf. *Immunotherapy* (2016).
43. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. *Nat Biotechnol* **31**, 71–75 (2013).
44. Kobayashi, E. *et al.* A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. *Nat Med* **19**, 1542–1546 (2013).
45. Kong, K. F. *et al.* Protein kinase C- η controls CTLA-4-mediated regulatory T cell function. *Nat Immunol* **15**, 465–472 (2014).
46. Leventhal, D. S. *et al.* Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells. *Immunity* **44**, 847–859 (2016).
47. Menager, M. M. & Littman, D. R. Actin Dynamics Regulates Dendritic Cell-Mediated Transfer of HIV-1 to T Cells. *Cell* **164**, 695–709 (2016).
48. Wang, S. *et al.* A light-controlled switch after dual targeting of proliferating tumor cells via the membrane receptor EGFR and the nuclear protein Ki-67. *Scientific Reports* **6**, 27032 (2016).
49. Wang, R. X., Chen, S., Jin, X. & Shao, Z. M. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. *Scientific Reports* **6**, 30091 (2016).

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (81572994, 81460432); Guangxi Natural Science Foundation (2015GXNSFDA139017); Guangxi Science and Technology Research and Technology Development Project (15104001-7); Project for Innovative Research Team in Guangxi Natural Science Foundation (2015GXNSFFA139001) and the University Scientific Research Project of Guangxi Department of Education (YB2014057).

Author Contributions

Y.H., Q.M., X.L. and Y.Z. designed the experiments. Y.H., Q.M. and J.H. prepared the fusion cells. J.S., Y.P., W.L. and Z.H. performed the experiments. Y.H., Q.M., J.H. and S.Z. analyzed the data. Y.H., Q.M., X.L. and Y.Z. wrote the manuscript. All authors read and approved the final manuscript.

Additional Information

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Huang, Y. *et al.* Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity. *Sci. Rep.* **7**, 46544; doi: 10.1038/srep46544 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017